A pivotal phase III trial of IBP-9414 for prevention of necrotizing enterocolitis in premature infants

Trial Profile

A pivotal phase III trial of IBP-9414 for prevention of necrotizing enterocolitis in premature infants

Planning
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Lactobacillus reuteri (Primary)
  • Indications Acute enterocolitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Infant Bacterial Therapeutics
  • Most Recent Events

    • 29 Nov 2017 New trial record
    • 24 Nov 2017 According to an Infant Bacterial Therapeutics, this trial is estimated to take place during 2018 - 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top